Company Profile
Amylyx Pharmaceuticals
Company Overview
Amylyx was started in 2013 by two Brown University students who had an ambitious goal: to improve the lives of people with neurodegenerative diseases by addressing the root cause. Their research and close collaboration with the ALS community ultimately resulted in our first commercial product, which is now approved in the U.S. and conditionally approved in Canada.
At Amylyx, we’re bringing together talented people like you who are guided by our values to be Audacious, Curious, Authentic, Engaging and Accountable in the fight against neurodegenerative diseases like, ALS, Alzheimer’s disease, Wolfram Syndrome and others.
Rediscover your purpose and reimagine your career at a company whose founders, mission, and culture are unlike any other in life sciences—in all the best ways.
Company History
Recent milestones include:
- The U.S. Food and Drug Administration (FDA) approved RELYVRIO™ in September of 2022
- Health Canada approved ALBRIOZA™ with conditions in Canada in June of 2022
- AMX0035 is currently under review with the European Medicines Agency
- 280 employees globally, with headquarters in Cambridge, MA, US and Amsterdam, the Netherlands -- and growing strong!